
US Customs updates Section 232 pharmaceutical import filing rules as global duties expand
US Customs and Border Protection has issued updated entry guidance for Section 232 duties on patented pharmaceuticals and ingredients. Coverage expanded to products of companies outside Annex III from 29 September 2026. Importers must select among HTSUS headings 9903.04.60 to 9903.04.70, applying origin, patent status, use and onshoring conditions accurately.
3 min readAI-drafted, expert reviewed

Section 232 pharmaceutical duties now cover non-Annex III companies
US Customs and Border Protection has published CSMS No. 70054007, updating entry instructions for Section 232 pharmaceutical duties under Presidential Proclamation 11020. Products of Annex III companies were covered from 31 July 2026. Goods from all other companies became subject when entered for consumption, or withdrawn from warehouse for consumption, from 12:01 am Eastern time on 29 September 2026.
The guidance reflects a 23 September Federal Register notice and corrections to the Harmonized Tariff Schedule of the United States (HTSUS). It covers specified classifications in Chapters 29 and 30 through headings 9903.04.60 to 9903.04.70.
Patent, origin, use and agreements determine the entry heading
Heading 9903.04.60 sets a 100% combined column one and Section 232 rate for covered patented pharmaceutical articles unless another heading applies. For covered products of Japan, European Union Member States, South Korea, Switzerland or Liechtenstein, heading 9903.04.62 sets the combined rate at 15%. United Kingdom-origin patented pharmaceutical articles enter under 9903.04.63 at a 0% additional rate.
Patented products under a qualifying onshoring plan use heading 9903.04.64 at 20%, increasing to 100% from 2 April 2030. A qualifying onshoring plan agreement paired with a most-favoured-nation pricing agreement can use 9903.04.65 at 0%, but that heading expires on 20 January 2029. If more than one proclamation rate applies, Customs says the lowest applicable rate controls.
Zero-rate headings remain condition-specific. Heading 9903.04.66 covers specified uses and listed jurisdictions. Heading 9903.04.67 covers generics and now expressly includes unpatented animal-health products. Heading 9903.04.68 covers dosage-form products made with a US-origin active pharmaceutical ingredient. Heading 9903.04.69 covers listed Chapter 29 or 30 articles that are not pharmaceuticals, or are neither patented nor generic. New heading 9903.04.70 covers articles and associated ingredients used solely for clinical trials, research and development or other non-commercial purposes.
Technical corrections narrow and clarify coverage
The corrected definition of pharmaceutical articles covers finished pharmaceutical products, their active pharmaceutical ingredients and key starting materials for those ingredients. Five codes were removed from Annex IV: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00 and 3004.49.00. Removal from Annex IV does not by itself establish the final entry treatment; filers must apply the corrected notes and product facts.
US-origin pharmaceutical products are not subject to these proclamation duties. Free-trade or preference eligibility does not displace an applicable Section 232 amount, while anti-dumping, countervailing and other duties may still apply. Drawback is available. Foreign-trade-zone admissions generally require privileged foreign status unless domestic status is eligible.
Related coverage includes EU trade measures on Chinese PBTC and the EU acetylsalicylic acid investigation.
Official source
US Customs and Border Protection CSMS No. 70054007, 28 September 2026content.govdelivery.com
Questions about this change
Does the US Section 232 pharmaceutical tariff apply a 100% rate to every medicine import?
No. US Section 232 pharmaceutical tariff treatment varies by product coverage, patent status, origin, intended use, active ingredient source and qualifying agreements. The guidance includes headings with 0%, 15% and 20% treatment.
Do free-trade agreements remove applicable US Section 232 pharmaceutical duties?
No. US Customs states that the applicable Section 232 pharmaceutical amount is collected in addition to an otherwise applicable preferential rate. Other applicable duties can also continue.

Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanFind out what this means for your products
Foresight follows changes like this one and shows where they reach your substances, products and markets.
Join 3,500+ professionals staying ahead
Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at

